ReviewJournal of biomedical science2026
Exploring CAR cell therapies beyond CAR-T for myeloid malignancies.
Review in Journal of biomedical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chimeric antigen receptor (CAR)-T cells have demonstrated remarkable efficacy in several hematologic malignancies; however, their application in myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remains limited, with no FDA-approved products to date. This limited progress largely reflects both efficacy challenges and safety concerns. CAR-T cells demonstrate poor trafficking and persistence within the bone marrow, limited activity against leukemia stem cells (LSCs), and reliance on antigens such as CD33 and CD123 that are also expressed on normal hematopoietic stem and progenitor cells, resulting in significant on-target off-tumor toxicity. Given these limitations, attention has increasingly shifted toward alternative CAR-engineered immune cells, including CAR-natural killer (CAR-NK) cells, CAR-invariant natural killer T (CAR-NKT) cells, and CAR-macrophages (CAR-Ms). These platforms offer unique advantages, such as intrinsic antitumor activity, distinct trafficking properties, reduced risk of graft-versus-host disease (GvHD), and potentially safer antigen recognition profiles, that may help overcome barriers faced by CAR-T cells. In this review, we highlight the challenges of applying conventional CAR-T cells to myeloid malignancies, examine emerging alternative CAR-cell platforms, and discuss how their unique biology and engineering strategies may provide safer, more effective, and more accessible therapeutic options for patients with these difficult-to-treat cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.